Epirubicin versus CMF as adjuvant therapy for stage I and II breast cancer: a prospective randomised study

Author: Colozza M.   Bisagni G.   Mosconi A.M.   Gori S.   Boni C.   Sabbatini R.   Frassoldati A.   Passalacqua R.   Bian A.R.   Rodino C.   Rondini E.   Algeri R.   Di Sarra S.   De Angelis V.   Cocconi G.   Tonato M.   on behalf of the Italian Oncology Group for Clinical Research GOIRC  

Publisher: Elsevier

ISSN: 0959-8049

Source: European Journal of Cancer, Vol.38, Iss.17, 2002-11, pp. : 2279-2288

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content